NCT06409338 Research on the Brain Mechanism of taVNS in Regulating PD Motor Symptoms
| NCT ID | NCT06409338 |
| Status | Recruiting |
| Phase | — |
| Sponsor | The First Affiliated Hospital with Nanjing Medical University |
| Condition | Parkinson Disease |
| Study Type | INTERVENTIONAL |
| Enrollment | 32 participants |
| Start Date | 2024-05-11 |
| Primary Completion | 2024-08 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 32 participants in total. It began in 2024-05-11 with a primary completion date of 2024-08.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study is a double blind comparative study exploring the neural underpinnings of taVNS modulating PD motor deficits. We hypothesize that taVNS might improve PD motor deficits by regulating the balance between excitation and inhibition in the primary motor cortex.
Eligibility Criteria
Inclusion Criteria: * (1) had a diagnosis of idiopathic PD according to the Movement Disorder Society Clinical Diagnostic Criteria for PD and ON-medication Hoehn and Yahr (H\&Y) stage ≤2, * (2) had stable pharmacotherapy for PD at least one month prior to the study, * (3) were aged between 40 and 80, * (4) signed written informed consent, * (5) can cooperate with the testing and taVNS treatment. Exclusion Criteria: * (1) with cognitive impairment, according to Montreal Cognitive Assessment (MOCA) \< 24; * (2) with severe tremor or levodopa-induced dyskinesia; * (3) with current intake of anticholinergics or any drugs that could induce cerebral functional change; * (4) with taVNS contraindications; * (5) received VNS treatment during the past six month; * (6) with concomitant severe neurologic, renal, cardiovascular, or hepatic disease.
Contact & Investigator
Zhang Kezhong
PRINCIPAL INVESTIGATOR
The First Affiliated Hospital with Nanjing Medical University
Frequently Asked Questions
Who can join the NCT06409338 clinical trial?
This trial is open to participants of all sexes, aged 40 Years or older, up to 80 Years, studying Parkinson Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06409338 currently recruiting?
Yes, NCT06409338 is actively recruiting participants. Contact the research team at kezhong_zhang1969@126.com for enrollment information.
Where is the NCT06409338 trial being conducted?
This trial is being conducted at Nanjing, China.
Who is sponsoring the NCT06409338 clinical trial?
NCT06409338 is sponsored by The First Affiliated Hospital with Nanjing Medical University. The principal investigator is Zhang Kezhong at The First Affiliated Hospital with Nanjing Medical University. The trial plans to enroll 32 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.